Skip to main content
Premium Trial:

Request an Annual Quote

Intervention Insights Raises $7.2M in Series B Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Personalized medicine software startup Intervention Insights of Grand Rapids, Mich., has reeled in $7.2 million in Series B financing, which it plans to use to expand its commercialization efforts, venture capital firm Beringea said Tuesday.

Led by Mich.-based Beringea, the funding round also included investments from Chrysalis Ventures, Hope Life Sciences, the Michigan Accelerator Fund, and other existing investors.

The firm plans to expand commercialization of its OncoInsights software product, which is based on a bioinformatics platform that it licensed from the Van Andel Research Institute.

The OncoInsights service matches a patient's cancer profile of more than 22,000 genes to the molecular mechanisms of action for more than 300 drugs. The service produces an electronic interactive report that ranks therapies that may target a patient's cancer in order to support oncologists as they make treatment decisions.

As part of the investment Beringea Managing Director Michael Gross and Chrysalis Managing Director Koleman Karleski have joined Intervention Insights' board of directors.

"Our new funding positions us well in the emerging personalized oncology market and allows us to expand our service offerings to support community oncologists," Jerry Callahan, Intervention Insights CEO, said in a statement.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.